---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021491"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:17:08.047762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q1 2023 net loss $16.3M; ENLIGHTEN I Phase 3 on track for 1H 2024 data

## Summary
- Net loss of $16.3M for Q1 2023, compared to $11.9M in Q1 2022.
- Cash, equivalents, and short-term investments $82.7M at March 31, 2023; cash runway into mid-Q2 2024.
- ENLIGHTEN I Phase 3 trial (LYR-210, pre-surgical CRS) enrollment ongoing; data expected 1H 2024.
- ENLIGHTEN II Phase 3 trial restarted enrollment in April 2023; completion expected H2 2024.
- BEACON Phase 2 trial (LYR-220, post-surgical CRS) enrollment complete; data expected Q4 2023.

## SEC filing metadata
- accession: 0000950170-23-021491
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/0000950170-23-021491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/lyra-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021491
- JSON: https://secwatch.observer/filing/0000950170-23-021491.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021491.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $16.3 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $16.3 million
  - Result: reported results
  source text: Net loss for the first quarter 2023 was $16.3 million compared to $11.9 million for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023021491/0000950170-23-021491-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.